Oppenheimer analyst Jay Olson lowered the firm’s price target on Incyte to $81 from $84 and keeps an Outperform rating on the shares. The firm thinks Jakafi and Opzelura sales will remain the key focus, especially with new competition in the Myelofibrosis and AD space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- AI Could Revolutionize Drug Discovery: A Look at Key Players
- Incyte downgraded to Underperform from Market Perform at BMO Capital
- Largest borrow rate increases among liquid names
- Incyte call volume above normal and directionally bullish
- Incyte: Final results of “Dutch auction” tender to purchase $1.6B in stock